Literature DB >> 26712054

Occult HBV reactivation induced by ibrutinib treatment: a case report.

Patrick de Jésus Ngoma, Benoît Kabamba, Geraldine Dahlqvist, Christine Sempoux, Nicolas Lanthier, Tony Shindano, Eric Van Den Neste, Yves Horsmans.   

Abstract

Ibrutinib is a small molecule that has been recently developped for the treatment of B cell malignancies. Common side effects are diarrhoea, nausea, fatigue, infections, neutropenia and thrombocytopenia. Here we report the first case of Hepatitis B virus reactivation in a 80 years old chronic lymphocytic leukaemia patient receiving ibrutinib, suggesting that such treatment must be associated with HBV screening. © Acta Gastro-Enterologica Belgica.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26712054

Source DB:  PubMed          Journal:  Acta Gastroenterol Belg        ISSN： 1784-3227            Impact factor:   1.316


  8 in total

Review 1.  Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies.

Authors:  Joshua S Davis; David Ferreira; Emma Paige; Craig Gedye; Michael Boyle
Journal:  Clin Microbiol Rev       Date:  2020-06-10       Impact factor: 26.132

2.  B cell receptor signaling drives APOBEC3 expression via direct enhancer regulation in chronic lymphocytic leukemia B cells.

Authors:  Zhiquan Wang; Huihuang Yan; Justin C Boysen; Charla R Secreto; Renee C Tschumper; Dania Ali; Qianqian Guo; Jian Zhong; Jiaqi Zhou; Haiyun Gan; Chuanhe Yu; Diane F Jelinek; Susan L Slager; Sameer A Parikh; Esteban Braggio; Neil E Kay
Journal:  Blood Cancer J       Date:  2022-07-01       Impact factor: 9.812

Review 3.  Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy.

Authors:  Man Fai Law; Rita Ho; Carmen K M Cheung; Lydia H P Tam; Karen Ma; Kent C Y So; Bonaventure Ip; Jacqueline So; Jennifer Lai; Joyce Ng; Tommy H C Tam
Journal:  World J Gastroenterol       Date:  2016-07-28       Impact factor: 5.742

Review 4.  Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia.

Authors:  Christopher Pleyer; Adrian Wiestner; Clare Sun
Journal:  Leuk Lymphoma       Date:  2018-05-15

Review 5.  Reactivation of hepatitis B virus infection in patients with hematologic disorders.

Authors:  Bo Wang; Ghulam Mufti; Kosh Agarwal
Journal:  Haematologica       Date:  2019-02-07       Impact factor: 9.941

6.  Chronic Hepatitis E Virus Infection during Lymphoplasmacytic Lymphoma and Ibrutinib Treatment.

Authors:  Bernhard Schlevogt; Volker Kinast; Julia Reusch; Andrea Kerkhoff; Dimas Praditya; Daniel Todt; Hartmut H Schmidt; Eike Steinmann; Patrick Behrendt
Journal:  Pathogens       Date:  2019-08-22

7.  Risk of HBV reactivation in relapsed or refractory diffuse large B-cell lymphoma patients receiving Bruton tyrosine kinase inhibitors therapy.

Authors:  Ying Ni; Lixia Gao; Yan Lu; Shiguang Ye; Lili Zhou; Wenbin Qian; Aibin Liang; Ping Li
Journal:  Front Immunol       Date:  2022-08-31       Impact factor: 8.786

8.  Hepatitis B Virus Reactivation under Ibrutinib Treatment in a Patient with Chronic Lymphocytic Leukemia

Authors:  Gülşen İskender; Dicle İskender; Mustafa Ertek
Journal:  Turk J Haematol       Date:  2020-04-06       Impact factor: 1.831
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.